Shad A, Magrath I
Division of Pediatric Hematology Oncology, Vincent T. Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC, USA.
Pediatr Clin North Am. 1997 Aug;44(4):863-90. doi: 10.1016/s0031-3955(05)70534-4.
Pediatric lymphomas are the third most common group of malignancies in children and adolescents. Unlike lymphomas in adults, pediatric lymphomas are diffuse, aggressive neoplasms with a propensity for widespread dissemination. Intensification of conventional treatment approaches along with improvements in supportive care have resulted in dramatic improvement in event-free survival rates of close to 90% in patients with B-cell lymphomas and only slightly lower in patients with T-cell lymphomas. Lymphoid neoplasms arise because of genetic changes that result in altered growth and differential patterns of lymphoid cells. The characterization of these molecular abnormalities and an understanding of their consequences has led to new approaches to diagnosis and the detection of minimal residual disease and also provides the basis for the future development of novel treatment approaches targeted specifically to the neoplastic cells.
小儿淋巴瘤是儿童和青少年中第三大最常见的恶性肿瘤组。与成人淋巴瘤不同，小儿淋巴瘤是弥漫性、侵袭性肿瘤，易于广泛播散。传统治疗方法的强化以及支持治疗的改善，使得B细胞淋巴瘤患者的无事件生存率显著提高，接近90%，T细胞淋巴瘤患者的无事件生存率略低。淋巴样肿瘤的发生是由于基因改变导致淋巴样细胞生长和分化模式改变。这些分子异常的特征及其后果的了解，导致了诊断和微小残留病检测的新方法，也为未来专门针对肿瘤细胞的新型治疗方法的开发提供了基础。
